Vicriviroc

DB06652InvestigationalSmall molecule

Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing...

Mechanism: Vicriviroc is a once daily oral inhibitor of CCR5. It noncompetitively binds to a hydrophobic pocket between transmembrance helices by the extracellular side of CCR5. This allosteric antagonism causes a conformational change in the protein preventing binding of gp120 to CCR5. This prevents the entry of HIV into the cell.
Curator reviewed
Primary indication: Investigated for use/treatment in HIV infection and viral infection.Curator reviewed
Formula / weight: C₂₈H₃₈F₃N₅O₂ · 533.6288 g/mol (avg)
Code names: MK-4176 · SCH-417690 · SCH-D

Resolves to

Compound

UNIITL515DW4QSCAS306296-47-9ChEMBLCHEMBL82301ChEBI94843

Structure

InChIKeyCNPVJJQCETWNEU-CYFREDJKSA-NSMILESCOC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F

Targets

P51681CCR5

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

549Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vicriviroc, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account